Intellia Therapeutics Corporate Overview 2024 Gene Editing

Intellia Therapeutics presents its gene editing platform and clinical pipeline, including lead programs NTLA-2001 (nexiguran ziclumeran) for ATTR amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency. The presentation outlines strategic priorities for 2024-2026, including Phase 3 trial initiations and collaborations with major partners including Regeneron.